FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN

美国食品和药物管理局最近批准了拓扑替康 (9-二甲氨基甲基-10-羟基喜树碱)和喜树碱(CPT-11) 随着喜树碱相关临床研究的加速发展 药物为人类癌症的成功治疗带来了新的希望， 包括目前尚无有效治疗方法的肿瘤。 拓扑替康的一种批准用途是治疗卵巢癌。 然而，拓扑替康的治疗范围很窄。为此， 技术进步，提供了一种直接和快速的手段 测量血浆药物水平将是非常有用的。我们表演了 拓扑替康和SN-38在人血浆和血浆中的直接荧光研究 微摩尔水平全血中拓扑替康的双光子研究 激发波长分别为730和820 nm。因为皮肤、血液和其他组织 在长波长下是半透明的，我们的结果表明 同种或非侵入性临床检测的可能性 喜树碱的双光子激发原位研究。

Recent FDA-approval of topotecan (9-dimethylaminomethyl-10hydroxycamptohecin) and camptosar (CPT-11) along with accelerated clinical development of related camptothecin drugs provides new hope for the successful treatment of human cancer, including neoplasms for which no effective treatment currently exist. One approved use of topotecan is for treatment of ovarian cancer. However, topotecan has a narrow therapeutic range. To this end, technological advances, which provide a direct and rapid means of measuring plasma drug levels would be of great utility. We performed direct fluorescence studies of topotecan and SN-38 in human plasma and topotecan in whole blood at micromolar level using two-photon excitation at 730 and 820 nm. Since skin, blood and other tissues are translucent at long wavelength, our results suggest the attractive possibility of homogenous or noninvasive clinical sensing of camptothecins in situ using two-photon excitation.